ArticleVeterinary research2026
Development of canine parvovirus-2-based recombinant pseudoviruses expression system: a potential vaccine platform.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Canine parvovirus-2 (CPV-2) and canine distemper virus (CDV) are two highly infectious and pathogenic pathogens that harm canids and various carnivores, and often cause co-infections in clinical settings. Although commercial attenuated live vaccines against CPV-2 and CDV have been widely used to prevent these viral infections, there are still issues of biosafety and insufficient protection against new variants, thus requiring novel vaccines. In this study, we developed a recombinant pseudovirus expression system based on the CPV-2 full-length infectious clone, and found that the recombinant CPV-2 pseudovirus expressing CDV H protein could efficiently protect dogs against both CPV-2 and CDV infections. We first designed a recombinant pseudovirus vector based on the CPV-2 backbone and established a stable cell system for the production of CPV-2 recombinant pseudoviruses carrying foreign genes. These pseudoviruses preserved the morphology and particle size of native CPV-2, while maintaining hemagglutination activity against porcine erythrocytes, and demonstrated the ability to effectively infect permissive cells to express the harbored foreign gene. Next, we produced a recombinant CPV-2 pseudovirus expressing CDV H protein, and the CPV-CDV recombinant pseudovirus induced effective cellular and humoral immune responses in dogs. The serum from CPV-CDV immunized dogs could effectively neutralize CPV-2 and CDV infections in susceptible cells. Importantly, CPV-CDV completely protected dogs against challenge with CPV-2 and CDV. In summary, we have successfully developed a stable production system of recombinant CPV-2 pseudoviruses, which has great potential for development as a vaccine platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.